US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 10:15:58 Source:healthViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Closing prices for crude oil, gold and other commodities
Next:What to expect in the California 20th District special election
You may also like
- State Supreme Court and Republican congressional primary elections top Georgia ballots
- Double Dutch! Chaotic European
- Paige Spiranac backs Rory McIlroy to WIN PGA Championship
- EA Sports College Football 25 comes out on July 19. Edwards, Ewers, Hunter are on standard cover
- Vatican makes fresh overture to China, reaffirms that Catholic Church is no threat to sovereignty
- Closing prices for crude oil, gold and other commodities
- Human rights group urges Thailand to stop forcing dissidents to return home
- Pictured: Woman, 81, killed in 'axe attack' at her sister
- Hundreds of hostages, mostly women and children, are rescued from Boko Haram extremists in Nigeria